Navigation Links
BCA Represents Independent Blood Centers at Phacilitate Cell & Gene Therapy Forum
Date:1/21/2013

West Warwick, RI (PRWEB) January 21, 2013

Blood Centers of America, Inc. (BCA) announced today it will play a leadership role in representing North American independent blood centers at this year's Phacilitate Cell & Gene Therapy Forum to be held January 28-30, 2013 in Washington, D.C.

BCA will be hosting one-on-one meetings with senior executives of leading cell therapy and cell-based immunotherapy companies, participating in sessions and high-profile networking events, and showcasing BCA member capabilities in the event's 3-day tradeshow.

"Participating in what is often described as one of the leading cell therapy industry conferences of the year is a great way to launch our 2013 initiative to raise the profile of BCA in the cell therapy industry and engage in one-on-one discussions about what BCA has to offer companies in the cell therapy sector," stated BCA's newly appointed CEO, Bill Block.

"BCA is a network of centers geographically dispersed throughout North America with considerable experience in collecting, processing and distributing regulatory-compliant, clinical-grade biologial materials", continued Block. "We are keen to engage cell therapy leadership in a discussion about how we can leverage BCA member infastructure and capabilities in the development and processing of cell therapy products and their safe and cost-effective delivery to patients."

About BCA

BCA is a member-owned organization comprised of 37 independent blood centers geographically dispersed throughout the North America, providing more than 46% of the U.S. blood supply. Along with their core business of providing a substantial portion of U.S. blood supply, BCA members provide a myriad of other services in cell therapies, blood management, therapeutic apheresis, tissue and cord blood banking, etc.

BCA provides thousands of units of biological materials annually to life science researchers, clinicians, therapeutic companies, or companies doing medical device, diagnostic or therapeutic development work.

BCA assists cell therapy companies with securing reliable and compliant sources for the cells used in their therapeutic products and/or pre-clinical research. Where a client need exceeds the capacity of a single center, BCA can assist with putting in place a multi-center supply agreement around cell collections, processing, storage or other handling.

In 2012, BCA generated over $6 million in custom products and services to cell therapy companies including patient-donor collections for autologous cell therapies in clinical trial and commercial distribution.

For more information about how BCA and its services, see http://www.bca.coop.

About the Cell & Gene Therapy Forum

Phacilitate's 9th Annual Cell & Gene Therapy Forum is firmly established as the world’s leading strategy and partnering event for senior decision makers from the global cell therapy, gene therapy and tissue engineered product sectors.

The Cell & Gene Therapy Forum is held along side the Vaccine Forum and the Protein Therapeutics Forum. For more information, see http://www.cgt-forum.com.

Read the full story at http://www.prweb.com/releases/2013/1/prweb10341060.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Butamax Early Adopters Group surpasses capacity targets with addition of Big River; Membership represents 11 production facilities and nearly 900 million gallons of ethanol capacity
2. Independent Marketing Automation Software Expert gives Positive review on MindMatrix's platform, AMP
3. New Organization Plans to Use Independent Peer Review to Put Millions of Hours Back into Research
4. BioNeutral Group Receives Positive Testing Results From A Global Independent Laboratory For Its Ygiene Sterilant Against Anthrax Spores
5. No on Prop. 37: French Rat Study Author Made Reporters Sign Confidentiality Agreements Prohibiting them from Consulting Independent Scientific Experts
6. China Integrated Energy Inc. Completes Independent Investigation
7. Synthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman
8. The Blood Sugar-Cardiac-Cancer Connection
9. Breakthrough Book From GLS Sciences Ends Blood Sugar Abuse in Time For The Holidays
10. Autoimmune disease retraining white blood cells
11. The Leading Edge Of Medical Innovation: New Prenatal Genetic Tests Use Moms Blood To Learn About Her Baby
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... Parallel ... clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module ... circle with the physician and clinical trial team. , Using the CONSULT module, patients ...
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in ... Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio ... practical tips, tools, and strategies for clinical researchers. , “The landscape of how ...
Breaking Biology Technology:
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
Breaking Biology News(10 mins):